<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Glioblastoma, IDH-Wildtype - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Glioblastoma, IDH-Wildtype</span>
        </nav>

        <header class="page-header">
            <h1>Glioblastoma, IDH-Wildtype</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0850335" target="_blank">
                        MONDO:0850335
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">diffuse glioma</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Glioblastoma, IDH-wildtype, is the most common and aggressive primary malignant brain tumor in adults. Under WHO 2021 classification, this molecularly defined entity requires absence of IDH1/2 mutations and presence of at least one of three molecular features: TERT promoter mutation, EGFR amplification, or combined gain of chromosome 7 and loss of chromosome 10 (+7/-10). These tumors are characterized by rapid growth, extensive infiltration, florid microvascular proliferation, and necrosis. Despite multimodal therapy, prognosis remains poor with median survival of 14-16 months. Key molecular alterations include TERT promoter mutations (80%), EGFR amplification (40-50%), PTEN loss, and homozygous CDKN2A deletion.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#histopathology">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">solid tumor</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Glioma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Giant Cell Glioblastoma
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Histological variant characterized by numerous bizarre multinucleated giant cells. May have slightly better prognosis than conventional glioblastoma. Often shows TP53 mutations.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Gliosarcoma
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Variant with biphasic pattern showing areas of glial differentiation and malignant mesenchymal (sarcomatous) component. Similar prognosis to conventional glioblastoma. Sarcomatous component often shows divergent molecular features.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Epithelioid Glioblastoma
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Aggressive variant with epithelioid morphology, frequent BRAF V600E mutations, and loss of INI1 expression. Often occurs in younger patients and may have worse prognosis than conventional glioblastoma.</div>
                    
                    
                    
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TERT Promoter Activation</div>
                
                <div class="item-desc">TERT promoter mutations (C228T or C250T) occur in approximately 80% of IDH-wildtype glioblastomas. These mutations create de novo ETS transcription factor binding sites, leading to TERT upregulation and telomerase reactivation. This enables unlimited replicative potential and is a defining molecular feature.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        telomere maintenance via telomerase
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007004" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        brain
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Chromosome 7 Gain and Chromosome 10 Loss</div>
                
                <div class="item-desc">Combined gain of chromosome 7 (+7) and loss of chromosome 10 (-10) is a defining molecular feature of IDH-wildtype glioblastoma, present in over 90% of cases. Chromosome 7 gain amplifies EGFR and MET. Chromosome 10 loss deletes PTEN and other tumor suppressors.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        chromosome organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051276" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚ö† ABNORMAL
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">EGFR/MET Pathway Activation</div>
                
                <div class="item-desc">EGFR is amplified in 40-50% and MET in 5% of glioblastomas. EGFR amplification is often accompanied by EGFRvIII, a constitutively active deletion variant lacking exons 2-7. These alterations drive proliferation through RAS/RAF/MAPK and PI3K/AKT pathways.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        MAPK cascade
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000165" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        phosphatidylinositol 3-kinase signaling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0014065" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">PTEN Tumor Suppressor Loss</div>
                
                <div class="item-desc">PTEN loss through chromosome 10 deletion, mutation, or epigenetic silencing occurs in 40-50% of glioblastomas. Loss of PTEN phosphatase activity leads to constitutive PI3K/AKT/mTOR pathway activation, promoting survival and growth.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        negative regulation of phosphatidylinositol 3-kinase signaling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0014067" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">PI3K/AKT/mTOR Pathway Hyperactivation</div>
                
                <div class="item-desc">Constitutive PI3K/AKT/mTOR activation through EGFR amplification, PIK3CA mutation, or PTEN loss promotes cell survival, proliferation, metabolism, and angiogenesis. This pathway is active in nearly all glioblastomas.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        apoptotic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006915" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Unlimited Replicative Potential</div>
                
                <div class="item-desc">Telomerase reactivation through TERT promoter mutations enables glioblastoma cells to bypass replicative senescence and achieve unlimited proliferative capacity, a hallmark of cancer.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Uncontrolled Cell Proliferation</div>
                
                <div class="item-desc">Multiple converging pathways (RTK signaling, PI3K/AKT/mTOR, cell cycle dysregulation) drive rapid proliferation characteristic of glioblastoma. High mitotic index and proliferation markers (Ki-67 often &gt;20%) are typical.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card" id="histopathology">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    Astrocytic Glioma
                    
                    <span class="histopathology-freq">VERY_FREQUENT</span>
                    
                </div>
                
                <div class="item-desc">Glioblastoma is a malignant astrocytic glioma.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17974913" target="_blank">PMID:17974913</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Malignant astrocytic gliomas such as glioblastoma are the most common and lethal"</div>
                
                
                <div class="evidence-explanation">Abstract groups glioblastoma among malignant astrocytic gliomas.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    TERT_Promoter_Activation[&#34;TERT Promoter Activation&#34;]
    PI3K_AKT_mTOR_Pathway_Hyperactivation[&#34;PI3K/AKT/mTOR Pathway Hyperactivation&#34;]
    Uncontrolled_Cell_Proliferation[&#34;Uncontrolled Cell Proliferation&#34;]
    Chromosome_7_Gain_and_Chromosome_10_Loss[&#34;Chromosome 7 Gain and Chromosome 10 Loss&#34;]
    Unlimited_Replicative_Potential[&#34;Unlimited Replicative Potential&#34;]
    PTEN_Tumor_Suppressor_Loss[&#34;PTEN Tumor Suppressor Loss&#34;]
    EGFR_MET_Pathway_Activation[&#34;EGFR/MET Pathway Activation&#34;]

    TERT_Promoter_Activation --&gt; Unlimited_Replicative_Potential
    Chromosome_7_Gain_and_Chromosome_10_Loss --&gt; EGFR_MET_Pathway_Activation
    Chromosome_7_Gain_and_Chromosome_10_Loss --&gt; PTEN_Tumor_Suppressor_Loss
    EGFR_MET_Pathway_Activation --&gt; Uncontrolled_Cell_Proliferation
    PTEN_Tumor_Suppressor_Loss --&gt; PI3K_AKT_mTOR_Pathway_Hyperactivation

    style TERT_Promoter_Activation fill:#dbeafe
    style PI3K_AKT_mTOR_Pathway_Hyperactivation fill:#dbeafe
    style Uncontrolled_Cell_Proliferation fill:#dbeafe
    style Chromosome_7_Gain_and_Chromosome_10_Loss fill:#dbeafe
    style Unlimited_Replicative_Potential fill:#dbeafe
    style PTEN_Tumor_Suppressor_Loss fill:#dbeafe
    style EGFR_MET_Pathway_Activation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">5</span>
            </div>
            
            
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Headache
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002315" target="_blank">
                            HP:0002315
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Seizure
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                            HP:0001250
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Cognitive Impairment
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100543" target="_blank">
                            HP:0100543
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Focal Neurological Deficit
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001269" target="_blank">
                            HP:0001269
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Personality Changes
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000751" target="_blank">
                            HP:0000751
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
                
    
    
            </div>
            
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TERT
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Promoter Mutation)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30333046" target="_blank">PMID:30333046</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TERT promoter (TERTp) mutations are found in the majority of World Health Organization (WHO) grade IV adult IDH wild-type glioblastoma (IDH-wt GBM)."</div>
                
                
                <div class="evidence-explanation">Abstract reports TERT promoter mutations in the majority of IDH-wildtype glioblastomas.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    EGFR
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Amplification)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PTEN
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Loss/Mutation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CDKN2A/CDKN2B
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Homozygous Deletion)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TP53
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Mutation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NF1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Mutation)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Maximal Safe Resection
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Aggressive surgical resection aims to maximize extent of resection while preserving neurological function. Greater extent of resection correlates with improved survival. Fluorescence-guided surgery with 5-ALA improves resection.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Radiation Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000014" target="_blank">
                            MAXO:0000014
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant treatment. Hypofractionated regimens may be used in elderly or poor performance status patients.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Temozolomide Chemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care. Temozolomide is an oral alkylating agent that crosses the blood-brain barrier. Benefit is greatest in MGMT methylated tumors.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Tumor Treating Fields (TTFields)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000944" target="_blank">
                            MAXO:0000944
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Alternating electric fields delivered via scalp arrays disrupt tumor cell mitosis. Added to maintenance temozolomide, TTFields extend median survival by approximately 5 months in newly diagnosed glioblastoma.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Bevacizumab
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces peritumoral edema and steroid requirements but does not clearly extend overall survival. FDA approved for recurrent disease.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    MGMT Promoter Methylation
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Glioblastoma, IDH-Wildtype
description: &gt;-
  Glioblastoma, IDH-wildtype, is the most common and aggressive primary malignant
  brain tumor in adults. Under WHO 2021 classification, this molecularly defined
  entity requires absence of IDH1/2 mutations and presence of at least one of three
  molecular features: TERT promoter mutation, EGFR amplification, or combined gain
  of chromosome 7 and loss of chromosome 10 (+7/-10). These tumors are characterized
  by rapid growth, extensive infiltration, florid microvascular proliferation, and
  necrosis. Despite multimodal therapy, prognosis remains poor with median survival
  of 14-16 months. Key molecular alterations include TERT promoter mutations (80%),
  EGFR amplification (40-50%), PTEN loss, and homozygous CDKN2A deletion.
categories:
- Central Nervous System Neoplasm
- Adult Brain Tumor
- Molecularly Defined Tumor
- High-Grade Glioma
parents:
- diffuse glioma
epidemiology:
- name: Most common primary malignant brain tumor
  description: Glioblastoma is the most common and most malignant primary brain tumor in adults.
  evidence:
  - reference: PMID:41569770
    supports: SUPPORT
    snippet: Glioblastoma, isocitrate dehydrogenase-wildtype CNS WHO grade 4 (formerly primary glioblastoma multiforme),
      is the most common and most malignant primary brain tumor.
    explanation: This abstract explicitly identifies IDH-wildtype glioblastoma as the most common and most malignant 
      primary brain tumor.
has_subtypes:
- name: Giant Cell Glioblastoma
  description: &gt;-
    Histological variant characterized by numerous bizarre multinucleated giant cells.
    May have slightly better prognosis than conventional glioblastoma. Often shows
    TP53 mutations.
- name: Gliosarcoma
  description: &gt;-
    Variant with biphasic pattern showing areas of glial differentiation and
    malignant mesenchymal (sarcomatous) component. Similar prognosis to conventional
    glioblastoma. Sarcomatous component often shows divergent molecular features.
- name: Epithelioid Glioblastoma
  description: &gt;-
    Aggressive variant with epithelioid morphology, frequent BRAF V600E mutations,
    and loss of INI1 expression. Often occurs in younger patients and may have
    worse prognosis than conventional glioblastoma.
pathophysiology:
- name: TERT Promoter Activation
  description: &gt;-
    TERT promoter mutations (C228T or C250T) occur in approximately 80% of
    IDH-wildtype glioblastomas. These mutations create de novo ETS transcription
    factor binding sites, leading to TERT upregulation and telomerase reactivation.
    This enables unlimited replicative potential and is a defining molecular feature.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: telomere maintenance via telomerase
    modifier: INCREASED
    term:
      id: GO:0007004
      label: telomere maintenance via telomerase
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Unlimited Replicative Potential
    description: Telomerase reactivation enables unlimited cell division
- name: Chromosome 7 Gain and Chromosome 10 Loss
  description: &gt;-
    Combined gain of chromosome 7 (+7) and loss of chromosome 10 (-10) is a
    defining molecular feature of IDH-wildtype glioblastoma, present in over 90%
    of cases. Chromosome 7 gain amplifies EGFR and MET. Chromosome 10 loss deletes
    PTEN and other tumor suppressors.
  biological_processes:
  - preferred_term: chromosome organization
    modifier: ABNORMAL
    term:
      id: GO:0051276
      label: chromosome organization
  downstream:
  - target: EGFR/MET Pathway Activation
    description: Chromosome 7 gain increases EGFR and MET copy number
  - target: PTEN Tumor Suppressor Loss
    description: Chromosome 10 loss eliminates PTEN
- name: EGFR/MET Pathway Activation
  description: &gt;-
    EGFR is amplified in 40-50% and MET in 5% of glioblastomas. EGFR amplification
    is often accompanied by EGFRvIII, a constitutively active deletion variant
    lacking exons 2-7. These alterations drive proliferation through RAS/RAF/MAPK
    and PI3K/AKT pathways.
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  - preferred_term: phosphatidylinositol 3-kinase signaling
    modifier: INCREASED
    term:
      id: GO:0014065
      label: phosphatidylinositol 3-kinase signaling
  downstream:
  - target: Uncontrolled Cell Proliferation
    description: Receptor tyrosine kinase signaling drives tumor growth
- name: PTEN Tumor Suppressor Loss
  description: &gt;-
    PTEN loss through chromosome 10 deletion, mutation, or epigenetic silencing
    occurs in 40-50% of glioblastomas. Loss of PTEN phosphatase activity leads to
    constitutive PI3K/AKT/mTOR pathway activation, promoting survival and growth.
  biological_processes:
  - preferred_term: negative regulation of phosphatidylinositol 3-kinase signaling
    modifier: DECREASED
    term:
      id: GO:0014067
      label: negative regulation of phosphatidylinositol 3-kinase signaling
  downstream:
  - target: PI3K/AKT/mTOR Pathway Hyperactivation
    description: Loss of PTEN removes brake on PI3K signaling
- name: PI3K/AKT/mTOR Pathway Hyperactivation
  description: &gt;-
    Constitutive PI3K/AKT/mTOR activation through EGFR amplification, PIK3CA mutation,
    or PTEN loss promotes cell survival, proliferation, metabolism, and angiogenesis.
    This pathway is active in nearly all glioblastomas.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
- name: Unlimited Replicative Potential
  description: &gt;-
    Telomerase reactivation through TERT promoter mutations enables glioblastoma
    cells to bypass replicative senescence and achieve unlimited proliferative
    capacity, a hallmark of cancer.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
- name: Uncontrolled Cell Proliferation
  description: &gt;-
    Multiple converging pathways (RTK signaling, PI3K/AKT/mTOR, cell cycle
    dysregulation) drive rapid proliferation characteristic of glioblastoma.
    High mitotic index and proliferation markers (Ki-67 often &gt;20%) are typical.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
histopathology:
- name: Astrocytic Glioma
  finding_term:
    preferred_term: Astrocytoma
    term:
      id: NCIT:C60781
      label: Astrocytoma
  frequency: VERY_FREQUENT
  description: Glioblastoma is a malignant astrocytic glioma.
  evidence:
  - reference: PMID:17974913
    supports: SUPPORT
    snippet: &#34;Malignant astrocytic gliomas such as glioblastoma are the most common and lethal&#34;
    explanation: Abstract groups glioblastoma among malignant astrocytic gliomas.

phenotypes:
- category: Neurological
  name: Headache
  frequency: VERY_FREQUENT
  description: &gt;-
    Headache from mass effect and increased intracranial pressure is common,
    often progressive and worse in the morning.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
- category: Neurological
  name: Seizure
  frequency: FREQUENT
  description: &gt;-
    Seizures occur in 25-40% of patients, more commonly with cortical involvement.
    May be focal or generalized.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- category: Neurological
  name: Cognitive Impairment
  frequency: FREQUENT
  description: &gt;-
    Progressive cognitive decline including memory, attention, and executive
    function deficits.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
- category: Neurological
  name: Focal Neurological Deficit
  frequency: FREQUENT
  description: &gt;-
    Motor weakness, sensory changes, aphasia, or visual field deficits depending
    on tumor location. Often progresses rapidly.
  phenotype_term:
    preferred_term: Hemiparesis
    term:
      id: HP:0001269
      label: Hemiparesis
- category: Neurological
  name: Personality Changes
  frequency: FREQUENT
  description: &gt;-
    Personality and behavioral changes, particularly with frontal lobe involvement.
    May include apathy, disinhibition, or emotional lability.
  phenotype_term:
    preferred_term: Personality changes
    term:
      id: HP:0000751
      label: Personality changes
genetic:
- name: TERT
  association: Promoter Mutation
  notes: &gt;-
    TERT promoter mutations (C228T or C250T) occur in approximately 80% of
    IDH-wildtype glioblastomas. Creates ETS binding sites leading to telomerase
    reactivation. One of three defining molecular features for diagnosis.
  evidence:
  - reference: PMID:30333046
    supports: SUPPORT
    snippet: &#34;TERT promoter (TERTp) mutations are found in the majority of World Health Organization (WHO) grade IV adult IDH wild-type glioblastoma (IDH-wt GBM).&#34;
    explanation: &#34;Abstract reports TERT promoter mutations in the majority of IDH-wildtype glioblastomas.&#34;
- name: EGFR
  association: Amplification
  notes: &gt;-
    EGFR amplification occurs in 40-50% of cases. EGFRvIII variant (deletion of
    exons 2-7) present in approximately 50% of EGFR-amplified tumors. EGFR
    amplification is one of three defining molecular features.
- name: PTEN
  association: Loss/Mutation
  notes: &gt;-
    PTEN is lost or mutated in 40-50% of glioblastomas through chromosome 10 loss,
    mutation, or promoter methylation. Loss activates PI3K/AKT signaling.
- name: CDKN2A/CDKN2B
  association: Homozygous Deletion
  notes: &gt;-
    Homozygous deletion of CDKN2A/CDKN2B at 9p21 occurs in approximately 60% of
    glioblastomas. Eliminates p16INK4a and p14ARF tumor suppressors, disrupting
    both RB and p53 pathways.
- name: TP53
  association: Somatic Mutation
  notes: &gt;-
    TP53 mutations occur in approximately 30% of IDH-wildtype glioblastomas,
    less common than in IDH-mutant tumors.
- name: NF1
  association: Somatic Mutation
  notes: &gt;-
    NF1 mutations occur in approximately 10-15% of glioblastomas, activating
    RAS/MAPK signaling. More common in mesenchymal subtype.
biochemical:
- name: MGMT Promoter Methylation
  notes: &gt;-
    MGMT promoter methylation occurs in approximately 35-45% of glioblastomas and
    predicts response to temozolomide. Silencing of MGMT DNA repair enzyme improves
    sensitivity to alkylating chemotherapy.
treatments:
- name: Maximal Safe Resection
  description: &gt;-
    Aggressive surgical resection aims to maximize extent of resection while
    preserving neurological function. Greater extent of resection correlates with
    improved survival. Fluorescence-guided surgery with 5-ALA improves resection.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Radiation Therapy
  description: &gt;-
    External beam radiation therapy (60 Gy in 30 fractions) is standard adjuvant
    treatment. Hypofractionated regimens may be used in elderly or poor performance
    status patients.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
- name: Temozolomide Chemotherapy
  description: &gt;-
    Concurrent and adjuvant temozolomide (Stupp protocol) is standard of care.
    Temozolomide is an oral alkylating agent that crosses the blood-brain barrier.
    Benefit is greatest in MGMT methylated tumors.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: Tumor Treating Fields (TTFields)
  description: &gt;-
    Alternating electric fields delivered via scalp arrays disrupt tumor cell
    mitosis. Added to maintenance temozolomide, TTFields extend median survival
    by approximately 5 months in newly diagnosed glioblastoma.
  treatment_term:
    preferred_term: cranial electrical stimulation
    term:
      id: MAXO:0000944
      label: cranial electrical stimulation
- name: Bevacizumab
  description: &gt;-
    Anti-VEGF monoclonal antibody used for recurrent glioblastoma. Reduces
    peritumoral edema and steroid requirements but does not clearly extend
    overall survival. FDA approved for recurrent disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: IDH-wildtype glioblastoma
  term:
    id: MONDO:0850335
    label: IDH-wildtype glioblastoma

classifications:
  icdo_morphology:
    classification_value: Glioma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Glioblastoma_IDH_Wildtype.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>